PRINCETON, NJ – April 16, 2024 – Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Certara Cloud, the unifying platform that integrates…
New, spacious location in Radnor, Pennsylvania will support the needs of company’s growing workforce and business, strengthen presence in the state RADNOR, PA – April 15, 2024 – Certara, Inc….
Learn about biosimilars, their benefits for patients who take biologic drugs, and how pharmaceutical companies demonstrate their bioequivalence to approved biosimilars.
TranscriptMany pharmaceutical industry professionals once considered standardizing regulatory writing style conventions unnecessary and time-consuming. However, the industry now recognizes its benefits for maximizing efficiency during regulatory submission development. The benefits of using…
Transcript: Hello, and welcome to Certara Talks. I’m Doctor Suzanne Minton, and I’m a director of content strategy at Certara . Today, I’m talking to my colleague, doctor Joshua Apgar….
Our free, downloadable CRF design checklist can help you design quality case report forms that meet all your study requirements.
In this video, Dr. Mark Sullivan, Managing Director of Medicines Development for Global Health, explains how Certara’s model-informed drug development expertise was used to support developing moxidectin as a treatment…
PRINCETON, N.J.— April 9, 2024– Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2024 after the…
This blog reviews the role of the endogenous biomarker, CP-1, for assessing OATP1B transporter-mediated drug-drug interactions and their clinical implications.
© 2025 Certara. All Rights Reserved. | Privacy policy
